A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

315 sites for NCT04497844

ATM Loss, +61 more biomarkers

Prostate Adenocarcinoma

abiraterone, +2 more drugs

hormone therapy, +1 more type

Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)

106 sites for NCT03742895

ATM Loss, +62 more biomarkers

Breast Carcinoma, +2 more conditions

olaparib

targeted therapy

Gemcitabine and Cisplatin Without Cystectomy for Patients With Muscle Invasive Bladder Urothelial Cancer and Select Genetic Alterations

259 sites for NCT03609216

ARID1A Loss, +122 more biomarkers

Bladder Urothelial Carcinoma

chemoradiotherapy, +6 more drugs

chemotherapy, +3 more types

A Modular Multi-Basket Trial to Improve Personalized Medicine in Cancer Patients (Basket of Baskets)

6 sites for NCT03767075

ATM Loss, +94 more biomarkers

Malignant Solid Tumor

atezolizumab

immunotherapy

Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast Cancer

1 site for NCT04849364

AKT1 Amplification, +141 more biomarkers

Invasive Breast Carcinoma

atezolizumab, +3 more drugs

chemotherapy, +2 more types

A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors

1 site for NCT04826341

ATM Loss, +64 more biomarkers

Malignant Solid Tumor, +1 more condition

berzosertib, +1 more drug

chemotherapy, +1 more type

Durvalumab and Olaparib for the Treatment of Prostate Cancer in Men Predicted to Have a High Neoantigen Load

1 site for NCT04336943

ATM Loss, +71 more biomarkers

Prostate Adenocarcinoma

durvalumab, +1 more drug

immunotherapy, +1 more type

Combination ATR and PARP Inhibitor (CAPRI) Trial With AZD6738 and Olaparib in Recurrent Ovarian Cancer

3 sites for NCT03462342

ATM Loss, +61 more biomarkers

Fallopian Tube Carcinoma, +3 more conditions

ceralasertib, +1 more drug

targeted therapy

Testing Olaparib in Patients With Advanced or Metastatic (Cancer That Has Spread) Bladder Cancer With DNA-Repair Genetic Changes

10 sites for NCT03375307

ABL1 Mutation, +57 more biomarkers

Bladder Carcinoma, +1 more condition

olaparib

targeted therapy

Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations

5 sites for NCT04042831

ARID1A Loss, +64 more biomarkers

Biliary Tract Carcinoma

olaparib

targeted therapy

Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the Elimusertib in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the Drug

16 sites for NCT04095273

ARID1A Loss, +125 more biomarkers

Adenocarcinoma of the Gastroesophageal Junction, +7 more conditions

elimusertib, +1 more drug

immunotherapy, +1 more type

The BARCODE 2 Study - The Use of Genetic Profiling to Guide Prostate Cancer Treatment

1 site for NCT02955082

ATM Loss, +62 more biomarkers

Prostate Adenocarcinoma

carboplatin

chemotherapy